Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in Glioblastoma

24 Jul 2019

Abstract excerpt

Amplification of epidermal growth factor receptor (EGFR) and active mutant EGFRvIII occurs frequently in glioblastoma (GBM) and contributes to chemo/radio-resistance in various cancers, especially in GBM. Elucidating the underlying molecular mechanism of temozolomide (TMZ) resistance in GBM could benefit cancer patients. A genome-wide screening under a clustered regularly interspaced short palindromic repeats...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Mechanisms and Therapy
Share to CRISPR and Genetic Engineering
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31508283
DOI: 10.1002/advs.201900782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genome‐Wide CRISPR‐Cas9 Screening Identifies NF‐κB/E2F6 Responsible for EGFRvIII‐Associated Temozolomide Resistance in GlioblastomaPMID 31508283Read ↗

Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistanceSemantic proximity Read ↗

Epigenomic perturbation of novel <i>EGFR</i> enhancers reduces the proliferative and invasive capacity of glioblastoma and increases sensitivity to temozolomideSemantic proximity Read ↗

Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme.Semantic proximity Read ↗

Exosomal transfer of long non-coding RNA SBF2-AS1 enhances chemoresistance to temozolomide in glioblastomaSemantic proximity Read ↗

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read ↗

Targeting the non-coding genome and temozolomide signature enables CRISPR-mediated glioma oncolysisSemantic proximity Read ↗

Variations in DNA Repair Genes and Intratumoral Genetic Heterogeneity in Temozolomide-Resistant Glioblastoma.Semantic proximity Read ↗

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR LibrariesSemantic proximity Read ↗

Integrated genetic screening reveals FEN1 as a driver of stemness and temozolomide resistance in glioblastomaSemantic proximity Read ↗

Unlocking Glioblastoma Vulnerabilities with CRISPR-Based Genetic ScreeningSemantic proximity Read ↗

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastomaSemantic proximity Read ↗

Loss of CD99L2 contributed to temozolomide resistance and glioblastoma tumorigenesis based on Genome-scale CRISPR/Cas9 screeningSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.